US · Healthcare · Biotechnology
EPS came in at -0.37 against a street estimate of -0.40 — a beat of 7.5%.
Analysts rate Relay Therapeutics Inc a strong buy (13 buy, 0 hold, 0 sell out of 13) with an average price target of $27.58.
| Fund | Stake |
|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 12.73% |
| FMR Inc | 9.18% |
| Casdin Capital, LLC | 7.32% |
| BlackRock Inc | 6.98% |
| Perceptive Advisors LLC | 6.44% |
| COMMODORE CAPITAL LP | 5.48% |
| State Street Corp | 4.62% |
| Vanguard Capital Management, LLC | 4.09% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Relay Therapeutics is a clinical-stage biotechnology company with no approved products and no product-sales revenue. • For the ni | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 net loss was $81.7 million, or $0.37 per share, compared with a $74.1 million net loss, or $0.43 per share, in Q3 2025. • | 2026-11-04 |
| Quarterly report · Q2 2026 RELAY THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash & Investments: $910.9 million combined (cash $121.2M + investments $789.7M | 2026-08-06 |
| Results announced · Q3 2026 RELAY THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash position: $910.9 million in cash, cash equivalents and investments as o | 2026-08-06 |
| Charter / bylaws change · Q2 2026 RELAY THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Authorized share increase: Common stock authorized shares raised from 300,000,000 to 450,0 | 2026-06-09 |
| Material agreement · Q2 2026 RELAY THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Stock offering size: 22,916,667 shares at $12.00 per share • Underwriter option exercised: | 2026-05-21 |
| Reg FD disclosure · Q2 2026 RELAY THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • 32 total patients enrolled and randomized in Phase 2 ReInspire trial of zovegalisib for va | 2026-05-19 |
| Quarterly report · Q1 2026 RELAY THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash Position: $204.6 million in cash and cash equivalents as of March 31, 2026 ( | 2026-05-05 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Relay Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.